BACKGROUND: Failure to normalize CD4(+) T-cell numbers despite effective antiretroviral therapy is an important problem in human immunodeficiency virus (HIV) infection. METHODS: To evaluate potential determinants of immune failure in this setting, we performed a comprehensive immunophenotypic characterization of patients with immune failure despite HIV suppression, persons who experienced CD4(+) T-cell restoration with therapy, and healthy controls. RESULTS: Profound depletion of all CD4(+) T-cell maturation subsets and depletion of naive CD8(+) T cells was found in immune failure, implying failure of T-cell production/expansion. In immune failure, both CD4(+) and CD8(+) cells were activated but only memory CD4(+) cells were cycling at increased frequency. This may be the consequence of inflammation induced by in vivo exposure to microbial products, as soluble levels of the endotoxin receptor CD14(+) and interleukin 6 were elevated in immune failure. In multivariate analyses, naive T-cell depletion, phenotypic activation (CD38(+) and HLA-DR expression), cycling of memory CD4(+) T cells, and levels of soluble CD14 (sCD14) distinguished immune failure from immune success, even when adjusted for CD4(+) T-cell nadir, age at treatment initiation, and other clinical indices. CONCLUSIONS: Immune activation that appears related to exposure to microbial elements distinguishes immune failure from immune success in treated HIV infection.
BACKGROUND: Failure to normalize CD4(+) T-cell numbers despite effective antiretroviral therapy is an important problem in human immunodeficiency virus (HIV) infection. METHODS: To evaluate potential determinants of immune failure in this setting, we performed a comprehensive immunophenotypic characterization of patients with immune failure despite HIV suppression, persons who experienced CD4(+) T-cell restoration with therapy, and healthy controls. RESULTS: Profound depletion of all CD4(+) T-cell maturation subsets and depletion of naive CD8(+) T cells was found in immune failure, implying failure of T-cell production/expansion. In immune failure, both CD4(+) and CD8(+) cells were activated but only memory CD4(+) cells were cycling at increased frequency. This may be the consequence of inflammation induced by in vivo exposure to microbial products, as soluble levels of the endotoxin receptor CD14(+) and interleukin 6 were elevated in immune failure. In multivariate analyses, naive T-cell depletion, phenotypic activation (CD38(+) and HLA-DR expression), cycling of memory CD4(+) T cells, and levels of soluble CD14 (sCD14) distinguished immune failure from immune success, even when adjusted for CD4(+) T-cell nadir, age at treatment initiation, and other clinical indices. CONCLUSIONS: Immune activation that appears related to exposure to microbial elements distinguishes immune failure from immune success in treated HIV infection.
Authors: Colleen F Kelley; Christina M R Kitchen; Peter W Hunt; Benigno Rodriguez; Frederick M Hecht; Mari Kitahata; Heide M Crane; James Willig; Michael Mugavero; Michael Saag; Jeffrey N Martin; Steven G Deeks Journal: Clin Infect Dis Date: 2009-03-15 Impact factor: 9.079
Authors: Wei Jiang; Michael M Lederman; Peter Hunt; Scott F Sieg; Kathryn Haley; Benigno Rodriguez; Alan Landay; Jeffrey Martin; Elizabeth Sinclair; Ava I Asher; Steven G Deeks; Daniel C Douek; Jason M Brenchley Journal: J Infect Dis Date: 2009-04-15 Impact factor: 5.226
Authors: Robert C Kaplan; Lawrence A Kingsley; Stephen J Gange; Lorie Benning; Lisa P Jacobson; Jason Lazar; Kathryn Anastos; Phyllis C Tien; A Richey Sharrett; Howard N Hodis Journal: AIDS Date: 2008-08-20 Impact factor: 4.177
Authors: Félix Gutiérrez; Sergio Padilla; Mar Masiá; José A Iribarren; Santiago Moreno; Pompeyo Viciana; José Hernández-Quero; Remedios Alemán; Francesc Vidal; Miguel Salavert; José R Blanco; Manuel Leal; Fernando Dronda; Santiago Perez Hoyos; Julia del Amo Journal: Curr HIV Res Date: 2008-03 Impact factor: 1.581
Authors: Gregory K Robbins; John G Spritzler; Ellen S Chan; David M Asmuth; Rajesh T Gandhi; Benigno A Rodriguez; Gail Skowron; Paul R Skolnik; Robert W Shafer; Richard B Pollard Journal: Clin Infect Dis Date: 2009-02-01 Impact factor: 9.079
Authors: Nicholas Funderburg; Angel A Luciano; Wei Jiang; Benigno Rodriguez; Scott F Sieg; Michael M Lederman Journal: PLoS One Date: 2008-04-02 Impact factor: 3.240
Authors: Lewis H Kuller; Russell Tracy; Waldo Belloso; Stephane De Wit; Fraser Drummond; H Clifford Lane; Bruno Ledergerber; Jens Lundgren; Jacqueline Neuhaus; Daniel Nixon; Nicholas I Paton; James D Neaton Journal: PLoS Med Date: 2008-10-21 Impact factor: 11.069
Authors: Peter J Kuebler; Megha L Mehrotra; Brian I Shaw; Kaitlyn S Leadabrand; Jeffrey M Milush; Vanessa A York; Patricia Defechereux; Robert M Grant; Esper G Kallás; Douglas F Nixon Journal: J Infect Dis Date: 2015-08-26 Impact factor: 5.226
Authors: Jesper F Højen; Thomas A Rasmussen; Karen Lise D Andersen; Anni A Winckelmann; Rune R Laursen; Jesper D Gunst; Holger J Møller; Mayumi Fujita; Lars Østergaard; Ole S Søgaard; Charles A Dinarello; Martin Tolstrup Journal: Mol Med Date: 2015-04-14 Impact factor: 6.354
Authors: E T Overton; D Kitch; C A Benson; P W Hunt; J H Stein; M Smurzynski; H J Ribaudo; P Tebas Journal: Clin Infect Dis Date: 2013-02-05 Impact factor: 9.079
Authors: Carey L Shive; Joseph C Mudd; Nicholas T Funderburg; Scott F Sieg; Benjamin Kyi; Doug A Bazdar; Davide Mangioni; Andrea Gori; Jeffrey M Jacobson; Ari D Brooks; Jeffrey Hardacre; John Ammori; Jacob D Estes; Timothy W Schacker; Benigno Rodriguez; Michael M Lederman Journal: J Infect Dis Date: 2014-02-28 Impact factor: 5.226
Authors: Wei Jiang; Souheil-Antoine Younes; Nicholas T Funderburg; Joseph C Mudd; Enrique Espinosa; Miles P Davenport; Denise C Babineau; Scott F Sieg; Michael M Lederman Journal: J Virol Date: 2014-02-12 Impact factor: 5.103
Authors: Rachel P Simmons; Eileen P Scully; Erin E Groden; Kelly B Arnold; J Judy Chang; Kim Lane; Jeff Lifson; Eric Rosenberg; Douglas A Lauffenburger; Marcus Altfeld Journal: AIDS Date: 2013-10-23 Impact factor: 4.177